Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression

Genes and Cancer

Volumn 5, Issue 3-4, 2014, Pages 71-83

  Kashyap, Vaishali ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bioinformatics; Prognosis; Prostate Cancer; Resistance; Yin Yang 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NITRIC OXIDE DONOR; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR YY1;

APOPTOSIS; BIOINFORMATICS; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TARGETING; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 84923108095     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Hyun JS. Prostate cancer and sexual function. World J Mens Health. 2012; 2:99-107.
2. La Vecchia C, Negri E, Franceschi S. Education and cancer risk. Cancer. 1992;70:2935-41.
3. Ghei M., Pericleous S., Kumar A., Miller R., Nathan S, and Maraj, B. H. Finger-guided transrectal biopsy of the prostate: a modified, safer technique. Ann R Coll Surg Engl. 2005;87:386–38.
4. Barry M. J. M. D. Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer N Engl J Med. 2001;344:1373-1377.
5. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Uroll. 1995;154:407-413.
6. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 1997; 277:1452-1455.
7. Leandri P, Rossignol G, Gautier J.R, Ramon J, Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases J. Urol. 1992;147:883–887.
8. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol. 2008;9:304.
9. Tennakoon JB, Shi Y, Han JJ, Tsouko E, White MA, Burns AR, Zhang A, Xia X, Ilkayeva OR, Xin L, Ittmann MM, Rick FG, Schally AV, Frigo DE. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene. 2013;doi:10.1038/onc.2013.463. (Advance online publication)
10. Labrie F. Hormonal therapy of prostate cancer. Prog Brain Res. 2010;182:321-41.
11. Golshayan AR, and Antonarakis ES, Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer Core Evid. 2013;8:27–35.
12. Hurley LH: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer. 2002;2:188–200.
13. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 14 Suppl 2005;1:35-48.
14. Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;1:131-141.
15. Sui G. The Regulation of YY1 in Tumorigenesis and its Targeting Potential in Cancer Therapy. Mol Cell Pharmacol. 2009;1:157–176.
16. Critical Reviews in Oncogenesis. Cell Cycle/Proliferation, Oncogenes/Tumor Suppressor Genes, Apoptosis/Survival. Begell House, inc. 2011;16:141-266.
17. Atchison M, Basu A, Zaprazna K, Papasani M. Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects. Crit Rev Oncog. 2011;16:143-61.
18. Zhang L, Cai X, Chen K, Wang Z, Wang L, Ren M, Huang A, Tang H. Hepatitis B virus protein up-regulated HLJ1 expression via the transcription factor YY1 in human hepatocarcinoma cells. Virus Res. 2011;157:76-81.
19. Inouye CJ, Seto E. Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23. J Biol Chem. 1994;269:6506–10.
20. Ren G, Zhang G, Dong Z, Liu Z, Li L, Feng Y, et al. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol. 2009;41:1094–101.
21. Satyamoorthy K, Park K, Atchison ML, Howe CC. The intracisternal A-particle upstream element interacts with transcription factor YY1 to activate transcription: pleiotropic effects of YY1 on distinct DNA promoter elements. Mol Cell Biol. 1993;11:6621-8.
22. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25:1125-42.
23. Shi Y, Seto E, Chang L-S, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 1991;67;377-388.
24. Deng Z, Wan M, Cao P, Rao A, Cramer SD, Sui G. Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene. 2009;28:3746-57.
25. Luke MP, Sui G, Liu H, Shi Y. Yin Yang 1 physically interacts with Hoxa11 and represses Hoxa11-dependent transcription. J Biol Chem. 2006;281:33226-32.
26. Santiago FS, Ishii H, Shafi S, Khurana R, Kanellakis P, Bhindi R, Ramirez MJ, Bobik A, Martin JF, Chesterman CN, Zachary IC, Khachigian LM. Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/ Cip1-Cdk4-cyclin D1 assembly. Circ Res. 2007;101:146-55.
27. Lee JS, Galvin KM, See RH, Eckner R, Livingston D, Moran E, Shi Y. Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev. 1995;9:1188-98.
28. Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci U S A. 1996;93:12845-50.
29. DeNigris F, Rossiello R, Schiano C, Arra C, Williams- Ignarro S, Barbieri A, Lanza A, Balestrieri A, Giuliano MT, Ignarro LJ, Napoli C. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CSCR4/ angiogenesis and metastasis. Cancer Res. 2008; 68:1797-1808.
30. Wang CC, Tsai MF, Hong TM, Chang GC, Chen CY, Yang WM, Chen JJ, Yang PC. The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene. 2005;24:4081-93.
31. Bonavida B, Baritaki S. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry. Crit Rev Oncog. 2011;16:211-26.
32. Hill, Brianne, “The Function of RKIP in the Tumourigenesis of Clear Cell Renal Cell Carcinoma” 2011. Open Access Dissertations and Theses. Paper 6095.
33. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
34. Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita- Esteruelas S, Peiro S, Baulida J, Franci C, Dedhar S, Larue L, Garcia de Herreros A. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene. 2004;23:7345-7354.
35. Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol. 2011;38:1683-1694.
36. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1-14.
37. DeNigris F, Zanella L, Cacciatore F, De Chiara A, Fazioli F, Chiappetta G, Apice G, Infante T, Monaco M, Rossiello R, De Rosa, G, Alberghini M, Napoli, C. YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma. BMC Cancer. 2011;11:472.
38. Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27:131-41.
39. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6:744-750.
40. Zaravinos A, Spandidos DA. Yin Yang 1 expression in human tumors. Cell Cycle. 2010;9:512-52.
41. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.
42. Chinnappan D, Xiao D, Ratnasari A, Andry C, King TC, Weber HC. Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol. 2009;34:1417-1423.
43. Bachmann I, Halvorsen O, Collett K, Stefansson IM, Straume O, Haukaas SA, SAlvensen HB, Otte AP, Akslen LA. EZH2 expression is associated with a high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. JClin Oncol. 2006;24:268-273.
44. Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, Vinkler R, Bonvier J, Delvenne P, Begon DY. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpressin in primary breast tumors. Breast Cancer Res. 2008;10:R9.
45. DeNigris F, Botti C, de Chiara A, Rossiello R, Apice G, Fazioli F, Fiorito C, Sica V, Napolic C. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006;42:2420-2424.
46. Wu S, Kasim V, Kano MR, Tanaka S, Ohba S, Miura Y, Miyata K, Liu X, Matsuhashi A, Chung UI, Yang L, Kataoka K, Nishiyama N, Miyagishi M. Transcription factor YY1 contributes to tumor growth by stabilizing hypoxia factor HIF-1α in a p53-independent manner. Cancer Research. 2013;17:1-40.
47. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16:5928-35.
48. Aaltonen K, Amini RM, Heikkila P, Aittomaki K, Tamminen A, Nevanlinna H, Blomqvist C. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer. 2009;100:1055-1060.
49. Moasser MM: The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469-6487.
50. Powe DG, Akhtar G, Habashy HO, Abdel-Fatah T, Rakha EA, Green AR, Ellis IO. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. Breast Cancer Research. 2009;11:R90.
51. Bondy, M; Ligon, BL. Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol. 1996;29:197–205.
52. Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System; IARC Press, Lyon. 2003;1:9–54.
53. Takahashi JA, Suzui H, Yasuda Y, Ito N, Ohta M, Jaye M, Fukumoto M, Oda Y, Kikuchi H, Hatanaka M. Gene expression of fibroblast growth factor receptors in the tissues of human gliomas and meningiomas. Biochem Biophys Res Commun. 1991;177:1–7.
54. Baritaki S, Chatzinikola AM, Vakis AF, Soulitzis N, Karabetsos DA, Neonakis I, Bonavida B, Spandidos DA. YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest. 2009;2:184-92.
55. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11:3686–96.
56. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC., Mori S, Chang JT, Ku W, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK. Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer Mol Cancer Res. February 2009;7:210.
57. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65.
58. Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 2005;62:3039–56.
59. Gill G, Ptashne M, Negative effect of the transcriptional activator GAL4. Nature. 1998;334:721–724.
60. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276-308.
61. Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther. 2005;5:63-74.
62. Denz A, Pilarsky C, Muth D, Rückert F, Saeger HD, Grützmann R. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J Surg Res. 2010;160:29-34.
63. Reiter GS. It’s not over till it’s over. AIDS Clin Care. 1998;10:20-1.
64. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res. 2002;1:113-21.
65. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol. 2002;20:82-8.
66. Zhigang Z, Wenlu S. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer. Prostate. 2007;67:1143-51.
67. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol. 2002;16:2323-37.
68. Tang S, Both S, Bentefour H, Paly JJ, Tochner Z, Efstathiou J, Lu HM. Improvement of prostate treatment by anterior proton fields. Int J Radiat Oncol Biol Phys. 2012;83:408-18.
69. Nicholson S, Whitehouse H, Naidoo K, Byers RJ. Yin Yang 1 in human cancer. Crit Rev Oncog. 2011;16:245-60.
70. Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher et al., Androgen receptor dependent regulation of Bc-xL expression: implication in prostate cancer progression, Prostate 2008;68:453-461.
71. Huerta-Yepez S, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol. 2006;120:297-309.
72. Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, et al. Nitric Oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin, Nitric Oxide. 1997;1:88-94.
73. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Garban H, Hongo F, Cheng G, et al., Nitric Oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 2004;23:4993-5003.
74. Kelleher ZT, Matsumoto A, Stamler JS, Marshall HE.NOS2 regulation of NF-kappaB by S-nitrosylation of p65. J Biol Chem. 2007;282:30667-72.
75. Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res. 2009;69:8376–8385.
76. Huerta-Yepez S, Baritaki S, Baay-Guzman G, Hernandez- Luna MA, Hernandez-Cueto A, Vega MI, Bonavida B. Contribution of either YY1 or Bcl(XL)-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and Bcl(XL) are overexpressed in prostate cancer. Nitric Oxide. 2013;29C:17-24.
77. Akalay I, Janji B, Hasmim M, Noman MZ, André F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, Sabbah M, Tan TZ, Keira JH, Hung NT, Thiery JP, Mami-Chouaib F, Chouaib S. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 2013;73:2418-27.
78. Myong NH. Loss of E-cadherin and Acquisition of Vimentin in Epithelial-Mesenchymal Transition are Noble Indicators of Uterine Cervix Cancer Progression. Korean J Pathol. 2012;46:341-8.
79. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, and Chinnaiyan AM. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia. 2004;6:6.
80. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790-2799
81. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA,Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162-70.
82. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
83. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D’Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2012;1:203-9.
84. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001;61:5974-5978.
85. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M. Gene expression analysis of prostate cancers. Mol Carcinog. 2002;33:25-35.
86. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62:4499-4506.
87. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003;63:3877-3882.
88. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostatecancer. Proc Natl Acad Sci U S A. 2004;101:811-6.
89. Bandyopadhyay S, Wang Y, Zhan R, Pai SK, Watabe M, Iiizumi M, Furuta E, Mohinta S, Liu W, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito K, Commes T, Piquemal D, Hai T, Watabe K. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res. 2006;66:11983-90.
90. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41-51.
91. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009;15:5794-5802.
92. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239-43